Mayne Pharma Group Limited (ASX:MYX) Announces 1H FY25 Market Update
Financial Performance
Mayne Pharma expects revenues of $210 – $215 million for 1H FY25, a 12 – 14% increase on 1H FY24. Underlying EBITDA is projected to reach $30 – $32 million, marking a 275 – 300% growth compared to 1H FY24. The company reports $124.9 million in cash and marketable securities as of 31 December 2024, a decrease of $4.6 million from October 2024.
Outlook for 2H FY25
Mayne Pharma anticipates continued growth in the second half of FY25, despite seasonal cost impacts from patient payment programs and increased promotional expenses for Women’s Health products.
Executive Comments
CEO and Managing Director Shawn Patrick O’Brien said, “We have experienced solid trading conditions in the first half as we execute against our corporate strategies, with robust revenue growth recorded particularly within our Women’s Health segment. We look forward to further updating our investors on our progress and plans at the half year results presentation in late February.”
Motley Fool contributor Lauren Surplice has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.